My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 95

    1.

    Determining sensitivity to rapamycin and its analogues in breast cancer patients.

    Witton CJ.

    Breast Cancer Res. 2005;7(1):41-2. Epub 2004 Dec 17. Review. No abstract available.

    PMID:
    15642182
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    2.

    Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.

    García-Morales P, Hernando E, Carrasco-García E, Menéndez-Gutierrez MP, Saceda M, Martínez-Lacaci I.

    Mol Cancer Ther. 2006 Sep;5(9):2172-81.

    PMID:
    16985050
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    3.

    Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

    Chang SB, Miron P, Miron A, Iglehart JD.

    J Surg Res. 2007 Mar;138(1):37-44. Epub 2006 Nov 15.

    PMID:
    17109887
    [PubMed - indexed for MEDLINE]

    Related citations

    4.

    Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

    Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB.

    Breast Cancer Res Treat. 2007 Dec;106(3):319-31. Epub 2007 Mar 9.

    PMID:
    17347776
    [PubMed - indexed for MEDLINE]

    Related citations

    5.

    Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

    Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.

    Oncogene. 2008 Jul 3;27(29):4086-95. Epub 2008 Mar 10.

    PMID:
    18332865
    [PubMed - indexed for MEDLINE]

    Related citations

    6.

    Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

    Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS.

    Breast Cancer Res Treat. 2008 Aug;110(3):477-83. Epub 2007 Sep 6.

    PMID:
    17805960
    [PubMed - indexed for MEDLINE]

    Related citations

    7.

    [The clinical relevance of the overexpression of HER-2 in breast cancer].

    Khosravi Shahi P, Pérez Manga G.

    An Med Interna. 2006 Mar;23(3):103-4. Spanish. No abstract available.

    PMID:
    16737428
    [PubMed - indexed for MEDLINE]

    Related citations

    8.

    Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y.

    Breast Cancer Res. 2005;7(6):R1097-110. Epub 2005 Nov 9.

    PMID:
    16457690
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    9.

    If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.

    Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA.

    J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210. Epub 2009 Oct 26. No abstract available.

    PMID:
    19858375
    [PubMed - indexed for MEDLINE]

    Related citations

    10.

    Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.

    Kim SH, Zukowski K, Novak RF.

    Anticancer Res. 2009 Apr;29(4):1143-50.

    PMID:
    19414357
    [PubMed - indexed for MEDLINE]

    Related citations

    11.

    Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

    Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S.

    Cancer Res. 2005 Apr 15;65(8):3336-46.

    PMID:
    15833867
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    12.

    Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

    J Clin Oncol. 2009 Jun 1;27(16):2630-7. Epub 2009 Apr 20.

    PMID:
    19380449
    [PubMed - indexed for MEDLINE]

    Related citations

    13.

    Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells.

    Okada T, Sawada T, Kubota K.

    Hepatogastroenterology. 2007 Oct-Nov;54(79):2129-33.

    PMID:
    18251175
    [PubMed - indexed for MEDLINE]

    Related citations

    14.

    Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

    Mol Cancer Ther. 2006 Nov;5(11):2676-84.

    PMID:
    17121914
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    15.

    Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.

    Johnston SR.

    Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1061s-1068s. Review.

    PMID:
    16467125
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    16.

    Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.

    Chiang CT, Way TD, Lin JK.

    Mol Cancer Ther. 2007 Jul;6(7):2127-38.

    PMID:
    17620442
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    17.

    Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.

    Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF.

    Gynecol Oncol. 2006 Mar;100(3):487-94. Epub 2005 Oct 24.

    PMID:
    16249016
    [PubMed - indexed for MEDLINE]

    Related citations

    18.

    Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.

    Wang LH, Chan JL, Li W.

    Int J Cancer. 2007 Jul 1;121(1):157-64.

    PMID:
    17304506
    [PubMed - indexed for MEDLINE]

    Related citations

    19.

    Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.

    Treeck O, Wackwitz B, Haus U, Ortmann O.

    Gynecol Oncol. 2006 Aug;102(2):292-9. Epub 2006 Jan 26.

    PMID:
    16443261
    [PubMed - indexed for MEDLINE]

    Related citations

    20.

    Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

    Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

    Cancer Res. 2006 Feb 1;66(3):1630-9.

    PMID:
    16452222
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filter your results:

      Find related data

      Recent activity

      You are here: NCBI > Literature > PubMed
      Write to the Help Desk